Published in Eur J Cancer on July 19, 2011
Immune regulation by atypical chemokine receptors. Nat Rev Immunol (2013) 1.17
Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acids Res (2013) 1.07
Ubiquitination of CXCR7 controls receptor trafficking. PLoS One (2012) 1.00
Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS One (2012) 0.98
Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res (2014) 0.98
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci (2014) 0.96
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br J Cancer (2012) 0.87
CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12. PLoS One (2014) 0.85
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer (2014) 0.85
CXCR7-mediated progression of osteosarcoma in the lungs. Br J Cancer (2013) 0.85
Chemokines, chemokine receptors and the gastrointestinal system. World J Gastroenterol (2013) 0.82
CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis (2014) 0.82
AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments. Oncol Rep (2015) 0.81
Chemokine receptor CXCR7 is a functional receptor for CXCL12 in brain endothelial cells. PLoS One (2014) 0.80
Aberrant proliferation in CXCR7+ endothelial cells via degradation of the retinoblastoma protein. PLoS One (2013) 0.79
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. J Transl Med (2013) 0.79
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. Cell Mol Immunol (2014) 0.79
CXCR7 expression disrupts endothelial cell homeostasis and causes ligand-dependent invasion. Cell Adh Migr (2014) 0.78
Oligonucleotide microarray identifies genes differentially expressed during tumorigenesis of DMBA-induced pancreatic cancer in rats. PLoS One (2013) 0.78
New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin (2017) 0.77
CXC chemokine receptor 7 expression in cervical intraepithelial neoplasia. Biomed Rep (2015) 0.77
A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma. Drug Des Devel Ther (2015) 0.77
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget (2016) 0.76
Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells. J Virol (2015) 0.76
Expression of chemokine receptor CXCR7 in colorectal carcinoma and its prognostic significance. Int J Clin Exp Pathol (2015) 0.75
Silencing of CXCR4 and CXCR7 expression by RNA interference suppresses human endometrial carcinoma growth in vivo. Am J Transl Res (2017) 0.75
EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway. J Exp Clin Cancer Res (2016) 0.75
Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol (2015) 0.75
Expression of C-X-C chemokine receptor type 7 in otorhinolaryngologic neoplasms. Singapore Med J (2016) 0.75
C-X-C motif receptor 7 in gastrointestinal cancer. Oncol Lett (2015) 0.75
2,3,7,8 Tetrachlorodibenzo-p-dioxin-induced RNA abundance changes identify Ackr3, Col18a1, Cyb5a and Glud1 as candidate mediators of toxicity. Arch Toxicol (2016) 0.75
Network-Based Analysis of Nutraceuticals in Human Hepatocellular Carcinomas Reveals Mechanisms of Chemopreventive Action. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells. Sci Rep (2017) 0.75
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (2009) 2.20
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol (2009) 1.95
Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J (2009) 1.90
Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis. J Hepatol (2010) 1.88
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Genetics of hepatobiliary carcinogenesis. Semin Liver Dis (2011) 1.79
ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology (2003) 1.70
Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet (2007) 1.68
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol (2007) 1.65
Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology (2008) 1.58
Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology (2004) 1.58
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology (2011) 1.51
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab (2004) 1.46
Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood (2005) 1.38
The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor. J Cell Biol (2007) 1.38
Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology (2013) 1.36
HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem (2007) 1.36
Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med (2009) 1.36
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res (2007) 1.35
Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis (2011) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Subtype classification of hepatocellular adenoma. Dig Surg (2010) 1.33
The mammalian Nm23/NDPK family: from metastasis control to cilia movement. Mol Cell Biochem (2009) 1.31
Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology (2009) 1.31
Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res (2010) 1.30
Infection with influenza virus induces IL-33 in murine lungs. Am J Respir Cell Mol Biol (2011) 1.29
BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci (2011) 1.27
Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol (2012) 1.25
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS (2003) 1.24
Squamous cell carcinoma arising in a hepatic forgut cyst. Pathol Res Pract (2002) 1.23
Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology (2007) 1.23
Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology (2003) 1.22
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet (2005) 1.22
Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis (2010) 1.21
Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol (2007) 1.21
Erk5 controls Slug expression and keratinocyte activation during wound healing. Mol Biol Cell (2008) 1.20
Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology (2006) 1.18
Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol (2008) 1.17
Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int (2008) 1.17
Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS One (2011) 1.16
Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology (2010) 1.15
Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes (2010) 1.13
Hepatocellular adenoma: what is new in 2008. Hepatol Int (2008) 1.12
Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. J Hepatol (2005) 1.12
Transcriptomic analysis of host immune and cell death responses associated with the influenza A virus PB1-F2 protein. PLoS Pathog (2011) 1.12
Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology (2013) 1.11
Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology (2002) 1.10
Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology (2007) 1.08
Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol (2005) 1.08
Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res (2008) 1.08
The HOX gene network in hepatocellular carcinoma. Int J Cancer (2011) 1.07
Differentiation of human basophils: an overview of recent advances and pending questions. J Leukoc Biol (2002) 1.07
Promising immunomodulatory effects of selected strains of dairy propionibacteria as evidenced in vitro and in vivo. Appl Environ Microbiol (2010) 1.06
Cytokine properties of prokineticins. FEBS J (2008) 1.06
The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol (2008) 1.06
Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma. J Natl Cancer Inst (2005) 1.06
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol (2012) 1.05
Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res (2010) 1.04
NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis. Eur J Immunol (2011) 1.04
Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol (2004) 1.04
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica (2013) 1.04
Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol (2002) 1.04
The nucleoside diphosphate kinase D (NM23-H4) binds the inner mitochondrial membrane with high affinity to cardiolipin and couples nucleotide transfer with respiration. J Biol Chem (2008) 1.02
The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest (2002) 1.02
A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst (2010) 1.02
Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res (2010) 1.01
Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology (2009) 1.00
Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol (2003) 1.00
CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med (2009) 1.00
Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int (2008) 1.00
CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis. J Biol Chem (2003) 0.99
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res (2007) 0.99
Novel lipid transfer property of two mitochondrial proteins that bridge the inner and outer membranes. Biophys J (2006) 0.99